Coagulation problems in liver disease.
Three topics are addressed in this manuscript: (1) the causes of abnormal hemostasis in cirrhosis; (2) the evaluation of hemostasis in cirrhotic patients before invasive procedures or in the presence of bleeding; and (3) the assessment of the effect of recombinant activated factor VII (rFVIIa; NovoSeven, Novo Nordisk A/S, Bagsvaerd, Denmark) on hemostatic function in cirrhotic patients. Laboratory experiments are described that could enhance the understanding of the effect of rFVIIa on blood coagulation during hemostasis in cirrhotic patients.
Rapaport
S I
SI
University of California, San Diego, USA. srapaport@ucsd.edu
D001777:Blood Coagulation; D001778:Blood Coagulation Disorders / Q000097:blood / Q000188:drug therapy / Q000209:etiology*; D015942:Factor VIIa / Q000627:therapeutic use; D005260:Female; D006801:Humans; D008107:Liver Diseases / Q000097:blood* / Q000150:complications*; D008297:Male; D011994:Recombinant Proteins / Q000627:therapeutic use; D013917:Thrombin
D011994:Recombinant Proteins; D015942:Factor VIIa; D013917:Thrombin